Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration

Laekna, Inc. announced that the Group has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LAE102, an internally discovered monoclonal antibody against ActRIIA, for the treatment of patients with obesity or metabolic diseases. The Company will work closely with the regulatory authorities to complete the application and targets to bring this precision therapy to obesity or metabolic patients who are in need of novel treatment options.